SynthesisJournal of cardiothoracic surgery2026
Drug-coated balloon alone versus atherectomy plus drug-coated balloon for treatment of femoropopliteal atherosclerotic disease: a meta-analysis.
Synthesis in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWe performed a systematic review and meta-analysis to compare the safety and efficacy of drug-coated balloon (DCB) with atherectomy (AT) plus DCB alone for the treatment of femoropopliteal artery disease (FAD).
methodsWe searched PubMed, the Cochrane Library, and EMBASE up to 31 December 2024. Observational studies and randomized controlled trials comparing DCB alone versus AT combined with DCB in the treatment of FAD were included. Outcomes were categorized as procedural outcomes, including bailout stenting, flow-limiting dissection, distal embolization, perforation, and hematoma, and clinical outcomes, including primary patency at 12-month, freedom from target lesion revascularization (fTLR) at 12-month, leg amputation, and all-cause mortality. Two reviewers independently assessed study eligibility, extracted data, and evaluated the risk of bias.
resultsEleven studies were included: 3 randomized controlled trials and 8 observational cohort studies, comprising 1296 participants. Compared to the AT + DCB group, when treating FAD, the DCB-alone group showed a higher incidence of bailout stenting (OR = 2.93, 95% CI [1.95, 4.39]; heterogeneity: I² = 7%) and flow-limiting dissection (OR = 4.46, 95% CI [2.53, 7.86]; heterogeneity: I² = 0%), but a lower risk of distal embolism (OR = 0.37, 95% CI [0.16, 0.84]; heterogeneity: I² = 0%). For other procedural outcomes, no significant differences were observed in perforation (OR = 0.66, 95% CI [0.28, 1.58]; heterogeneity: I² = 0%) or hematoma (OR = 0.83, 95% CI [0.38, 1.81]; heterogeneity: I² = 0%). For clinical outcomes, there were no significant differences between the two groups in fTLR at 12-month (OR = 0.81, 95% CI [0.57, 1.16]; heterogeneity: I² = 24%), primary patency at 12-month (OR = 0.92, 95% CI [0.68, 1.24]; heterogeneity: I² = 0%), all-cause mortality (OR = 1.15, 95% CI [0.74, 1.78]; heterogeneity: I² = 31%), or amputation (OR = 1.79, 95% CI [0.90, 3.56]; heterogeneity: I² = 0%).
conclusionOur meta-analysis demonstrated that AT + DCB did not show significant clinical superiority over DCB alone in terms of 12-month primary patency or fTLR. This combined approach did, however, significantly reduce the occurrence of flow-limiting dissections and decrease the need for bailout stenting. This highlights its potential as a strategy for achieving "graft-free residual" treatment in FAD. If further technical refinements can reduce the higher risk of distal embolization seen with the addition of atherectomy, longer term clinical benefits may be realized by reducing the risk of ISR. Importantly, these findings emphasize the necessity for large-scale, multicenter randomized controlled trials with extended follow-up periods to confirm the clinical efficacy and safety of this combined therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.